GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Tangible Book per Share

Champions Oncology (Champions Oncology) Tangible Book per Share : $-0.18 (As of Jan. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Champions Oncology's tangible book value per share for the quarter that ended in Jan. 2024 was $-0.18.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Champions Oncology Tangible Book per Share Historical Data

The historical data trend for Champions Oncology's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Tangible Book per Share Chart

Champions Oncology Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.37 0.53 0.65 0.32

Champions Oncology Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.32 0.12 -0.02 -0.18

Competitive Comparison of Champions Oncology's Tangible Book per Share

For the Biotechnology subindustry, Champions Oncology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Price-to-Tangible-Book falls into.



Champions Oncology Tangible Book per Share Calculation

Champions Oncology's Tangible Book Value Per Share for the fiscal year that ended in Apr. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(4.636-0-0.335)/13.5442
=0.32

Champions Oncology's Tangible Book Value Per Share for the quarter that ended in Jan. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-2.058-0-0.335)/13.5938
=-0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Champions Oncology  (NAS:CSBR) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Champions Oncology Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology (Champions Oncology) Business Description

Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093

Champions Oncology (Champions Oncology) Headlines

From GuruFocus